Taiwan

Current Distributors Profiles

Our network has distributors that have product categories that include Laboratory Consumables and Reagents, Laboratory Equipment, and Custom Services.  They have partnerships with key local sales and local distribution partners throughout the country which enables a cost-efficient method of selling products into thes market.  Sales and Marketing outreach programs utilizing social marketing platforms such as FaceBook, Instagram, @Line, and Mail Chimp.  These distributors add value by stocking superior consumables and reagents that end users trust, offering quick and easy sales and delivery service, offer local language technical support in country, and performing product seminar/workshops/webinars.  These distributors also staff a highly knowledgeable field sales team.  Their major customer segments include well-funded research units, thriving biotech companies, and National Core Laboratories.

Taiwan also has a distribution system which has a confusing mix of distributors and dealers.  b2b connect has a number of niche distributors in Taiwan that we can contact to see which one may be a good fit with your product portfolio.

 Market

In Taiwan, 5+2 equals more than seven. The 5+2 Innovative Industries Plan, championed by President Tsai Ing-wen, aims to grow the nation’s economy by building five pillar industries, including biopharma, plus “high-value” agriculture and a regenerative/reuse or “circular” economy). That program was launched in 2016, when a decade of successful activity helped the biotech industry more-than-double to NT$109.7 billion ($3.55 billion), while pharma grew to NT$159.8 billion ($5.2 billion).

Taiwan has committed to a combined biopharma and medical device industry totaling NT$1 trillion ($32.4 billion) by 2025, in part by developing and marketing 20 new drugs, and establishing at least 10 biotech and health-related corporate giants or “flagship brands,” either through organic growth or acquisitions. Taiwan took its latest step forward on October 15 when Tsai led dignitaries in formally opening the 25-hectare (61.8-acre) National Biotechnology Research Park. The NT$20 billion (US$648 million) park consists of seven buildings, including a bioinformatics facility, incubation hub, and translational medicine research center.

Taiwan’s strengths include R&D (fifth with $35.757 billion in 2016, according to OECD) and number of companies (fifth with 845—520 applied biotechs and 320 pharmas, according to 2016 statistics from the Ministry of Economic Affairs [MOEA]’s Biotechnology and Pharmaceutical Industries Promotion Office). Taiwan finishes seventh in both jobs (38,719 of 2016, according to MOEA) and IPOs ($35 million from the U.S. IPO of Taiwan Liposome), and eighth in patents (853 listing at least one Taiwan inventor, according to WIPO).